http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#Head http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#assertion http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#provenance http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#pubinfo http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#assertion http://purl.obolibrary.org/obo/DOID_2957 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2957 http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08903 http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association http://www.w3.org/2000/01/rdf-schema#label sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adults 18 years and older with pulmonary multi drug resistant tuberculosis mdr tb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot this indication is approved under accelerated approval based on time to sputum culture conversion see clinical studies 14 sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults 18 years and older with pulmonary multi drug resistant tuberculosis mdr tb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot 1 2 1 this indication is approved under accelerated approval based on time to sputum culture conversion continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1 14 limitations of use 1 14 limitations of use do not use sirturo for the treatment of latent infection due to mycobacterium tuberculosis drug sensitive tuberculosis extra pulmonary tuberculosis infections caused by non tuberculous mycobacteria the safety and efficacy of sirturo in the treatment of hiv infected patients with mdr tb have not been established as clinical data are limited see clinical studies 14 http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08903 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#provenance http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#pubinfo http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig http://purl.org/nanopub/x/hasSignature Gz5Y7vb3c16ftCWWmPDCMCxkP8qsrfvT+3YKlVThKP+6r5Wgd+MEt72HCv1qck/fyp3vokm18ZetHzTCL/ACYsmqJz42VRGfl5q7wmQwo++pIM6r9J1zVKjKJmkJcYIR0K/Y5j7MUpCxpBrxdcRd1fX2b3nHo39sCm9j2wDwwPQ= http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://purl.org/dc/terms/created 2021-07-03T14:32:24.283+02:00 http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs